Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: Triple vs Dual Therapy in Minority Hypertension
NCT00942994Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren, amlodipine and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jun 2009; status: completed.
02
Drugs
aliskirenamlodipinehydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00942994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942994.